Division of Infectious Diseases, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
J Glob Antimicrob Resist. 2021 Dec;27:299-302. doi: 10.1016/j.jgar.2021.09.015. Epub 2021 Nov 12.
Real-world data regarding the effectiveness of meropenem/vaborbactam (MVB) in the treatment of carbapenem-resistant Enterobacterales (CRE) infections remain limited. In this retrospective case series, we describe the outcomes of patients who received MVB for serious CRE infections.
This study included adult patients with MVB-susceptible CRE infection who received ≥48 h of MVB. Clinical and microbiological outcomes were ascertained via chart review.
Among 15 patients with CRE infection who were treated with MVB, 9 (60.0%) had a positive clinical response. Among five patients with CRE bone and joint infection, three (60.0%) experienced a positive clinical response. One patient developed a microbiologically confirmed recurrent CRE infection and one patient developed Clostridioides difficile infection.
MVB was well tolerated and effective for the majority of patients in this case series.
有关美罗培南/维巴利汀（MVB）治疗碳青霉烯类耐药肠杆菌科（CRE）感染的真实世界数据仍然有限。在这项回顾性病例系列研究中，我们描述了接受 MVB 治疗严重 CRE 感染的患者的结局。
本研究纳入了接受 MVB 治疗且药敏试验显示对 MVB 敏感的 CRE 感染的成年患者，这些患者接受了至少 48 小时的 MVB 治疗。通过病历回顾来确定临床和微生物学结局。
在接受 MVB 治疗的 15 例 CRE 感染患者中，有 9 例（60.0%）获得了阳性临床应答。在 5 例 CRE 骨和关节感染患者中，有 3 例（60.0%）获得了阳性临床应答。1 例患者发生了微生物学确诊的复发性 CRE 感染，1 例患者发生了艰难梭菌感染。
在本病例系列研究中，MVB 被大多数患者耐受良好且治疗效果良好。
